Pebblebrook Hotel Trust (PEB) offers preferred stocks with yields above 8%, but these come with higher operational and credit risks compared to safer REITs such as PSA. PEB's preferred stock spreads to Treasuries have narrowed to about one percentage point above those of investment-grade REITs, despite PEB lacking a credit rating and operating in the cyclical hotel sector. This increases its vulnerability to economic downturns. Investors are advised to consider safer alternatives like PSA, which provide similar yields but with better credit quality and lower risk.
Pebblebrook Hotel Trust (PEB) is the story's subject. For readers following US Real Estate stocks, here is Pluang's market snapshot as of Sep 24, 2026 23:32 WIB: Out of 26 priced Real Estate-sector US stocks, 10 rose and 16 fell. Notable movers include CCI at USD 68.64 with a -2.26% change and 100% buy order activity, ARR at USD 14.32 with a -1.92% change and 58% sell order activity, and LTC at USD 43.29 with a +1.76% change and 97% sell order activity.
Costco reported a strong Q4 earnings per share (EPS) of $6.75, surpassing analyst expectations of $6.54, helped by tariff refunds. Although quarterly revenue of $93.87 billion slightly missed the $94.97 billion forecast, net sales rose 11.2% year-ove...
Vistry Group reported a significant first-half pre-tax loss of £661.3 million, driven by a £475 million goodwill impairment and increased building safety costs. Revenue fell to £1.42 billion, and operational performance weakened with fewer home compl...
Vail Resorts is set to report its Q3 2026 earnings on September 28, with analysts forecasting a loss per share around -$5.30 and revenue near $271 million, indicating flat performance year-over-year. The company’s financial health shows a high Debt-t...
Western Union faces multiple analyst downgrades with price targets cut to as low as $6.00, reflecting concerns over its profitability and competitive pressures from fintech rivals. The stock has fallen over 15% in the past month, trading near $6.00, ...
Citigroup lowered ACADIA Pharmaceuticals' price target from $40 to $33 after its Alzheimer's drug remlifanserin missed the primary goal in a mid-stage trial, causing a 10.5% stock drop. Despite this, Citigroup kept a "Buy" rating, citing promising se...
